logo
Venice locals win bid to convert abandoned island into sanctuary

Venice locals win bid to convert abandoned island into sanctuary

Daily Mail​a day ago
A small island near Venice once used as a plague pit is set to become a public park for the city's residents. Part of Poveglia, an island south of the Italian city, has been deserted and closed to visitors for decades, its dilapidated hospital buildings frozen in time, its imposing fort now abandoned and its rumored mass graves still hidden.
Its grisly past covers both the countless unknown plague victims thought to have died on the island and the lobotomies reputed to have occurred there when the hospital served as a mental asylum in the 1920s. In 2014 the Italian government sold the island for £400,000 as part of an Italian government strategy to sell off unused property to address its budget crisis.
But a group of Venetians launched a campaign to protect the island from commercial development, calling themselves 'Poveglia For Everyone' (PFE). Following a protracted battle, PFE won control over the island. The activist group won a six-year lease, beginning next month, beating competitors including Venice's mayor Luigi Brugnaro.
The grassroots group asked Venetians to donate money to help preserve the island from development and turn it into an oasis for those wishing to escape the hustle and bustle of the tourist-laden city. Patrizia Veclani, one of the founders of Poveglia for Everyone, told the Times: 'We woke up with a nest egg of €460,000 (£400,887) and a community full of high-level professional skills.'
Her group will pay little more than €1,000 (£871) a year for the renewable lease. PFE says it is joining forces with the University of Verona to transform the northern part of the island 'into a lagoon urban park open to citizens and respectful of the ecosystem and the landscape elements that characterise the lagoon.'
The group faces an uphill battle to regenerate the island, however, as there is currently no water or electricity, nor is there a proper pier. Earlier this year, furious Neapolitan locals attempted to crowdfund the purchasing 'back' of a tiny island in the shadows of Mount Vesuvius after it was listed for sale at over £8million.
The island of Punta Pennata, which spans an area of just 70x500 metres, lays a mere 100 meters offshore the town of Bacoli in the Gulf of Naples. Despite being a favorite fishing retreat of locals for decades, the rocky peninsula was put up for sale by luxury auctioneers Sotheby's. Residents and officials from neighboring towns are not simply accepting the island's sale though, with Bacoli mayor Josi Della Rangione leading the campaign to place Punta Pennata under the stewardship of the local community.
Italy as a nation has already dealt with vast levels of overtourism and a plethora of foreign tycoons buying up similarly prime real estate from under local's noses. In a bid to stop Punta Pennata from falling into the hands of another exorbitantly wealthy businessperson or celebrity, Mr Della Regione drummed up support from all over Italy in the hopes that the local community can raise enough funds to 'buy back' the island.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A woman has died after being licked by a dog. Here's what you need to know
A woman has died after being licked by a dog. Here's what you need to know

Times

time32 minutes ago

  • Times

A woman has died after being licked by a dog. Here's what you need to know

They share our sofa and sprawl across our laps. But should we let our dogs lick us? Last week it emerged that June Baxter, 83, a retired legal secretary, died of septic shock after her leg injury was licked by a dog and this led to an infection. Tests from the wound found Pasteurella multocida, a bacteria present in about 50 per cent of dogs' mouths, which typically does a dog no harm. No, although very few incidents of serious injury or death caused by Pasteurella multocida from a dog lick have been recorded. They include an 85-year-old woman with a pet dog who had Pasteurella multocida and died with multiple organ failure after developing septic shock. In 2023 the case report authors in the journal BMC Geriatrics said that highlighting her death was 'important, given the growing cohort of elderly pet-owners seeking medical care'.

Demand for weight loss drugs is becoming unsustainable, say pharmacists
Demand for weight loss drugs is becoming unsustainable, say pharmacists

The Guardian

time38 minutes ago

  • The Guardian

Demand for weight loss drugs is becoming unsustainable, say pharmacists

Demand for weight loss drugs is becoming so 'unsustainable' that demand may soon outstrip supply, pharmacists have warned. The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved. The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately. During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them. 'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said. The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added. New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds. The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34. Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies. 'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair. 'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.' Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs. The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites. A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years. 'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added. 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.' About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years. Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added. 'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.

Roche to investigate whether new drug can delay or prevent Alzheimer's disease
Roche to investigate whether new drug can delay or prevent Alzheimer's disease

Reuters

time2 hours ago

  • Reuters

Roche to investigate whether new drug can delay or prevent Alzheimer's disease

July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store